Literature DB >> 11316325

Melatonin prevents endotoxin-induced circulatory failure in rats.

C C Wu1, C W Chiao, G Hsiao, A Chen, M H Yen.   

Abstract

The pineal secretory product melatonin was found to exert protective effects in septic shock. In a host infected by bacterial lipopolysaccharide (LPS), the expression and release of proinflammatory tumor necrosis factor-alpha (TNF-alpha) is rapidly increased, suggesting that TNF-alpha is associated with the etiology of endotoxic shock. Recent reports show that the expression of NO synthase (NOS) II and the production of superoxide anion (O2*-) also contribute to the pathophysiology of septic shock. In the present study we demonstrate that melatonin prevents circulatory failure in rats with endotoxemia and improves survival in mice treated with a lethal dose of LPS. The beneficial hemodynamic effects of melatonin in the endotoxemic animal appear to be associated with the inhibition of (i) the release of TNF-alpha in plasma, (ii) the expression of NOS II in liver, and (iii) the production of O2*- in aortae. In addition, the infiltration of polymorphonuclear neutrophils into the liver from the surviving LPS mice treated with melatonin was reduced. Thus, our results support the clinical use of melatonin in endotoxemia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11316325     DOI: 10.1034/j.1600-079x.2001.300303.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  22 in total

Review 1.  Hepatoprotective actions of melatonin: possible mediation by melatonin receptors.

Authors:  Alexander M Mathes
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

Review 2.  A review of the multiple actions of melatonin on the immune system.

Authors:  Antonio Carrillo-Vico; Juan M Guerrero; Patricia J Lardone; Russel J Reiter
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 3.  Utilizing melatonin to combat bacterial infections and septic injury.

Authors:  Wei Hu; Chao Deng; Zhiqiang Ma; Dongjin Wang; Chongxi Fan; Tian Li; Shouyin Di; Bing Gong; Russel J Reiter; Yang Yang
Journal:  Br J Pharmacol       Date:  2017-03-21       Impact factor: 8.739

4.  Administration of Exogenous Melatonin After the Onset of Systemic Inflammation Is Hardly Beneficial.

Authors:  Lisa Brencher; Maren Oude Lansink; Katharina Effenberger-Neidnicht
Journal:  Inflammation       Date:  2017-10       Impact factor: 4.092

5.  Thaliporphine increases survival rate and attenuates multiple organ injury in LPS-induced endotoxaemia.

Authors:  Chin-Wei Chiao; Shoei-Sheng Lee; Chin-Chen Wu; Ming-Jai Su
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-01-15       Impact factor: 3.000

6.  Immune stimulation by exogenous melatonin during experimental endotoxemia.

Authors:  Katharina Effenberger-Neidnicht; Lisa Brencher; Martina Broecker-Preuss; Tim Hamburger; Frank Petrat; Herbert de Groot
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

Review 7.  Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas.

Authors:  Russel J Reiter; Sergio Rosales-Corral; Dun Xian Tan; Mei Jie Jou; Annia Galano; Bing Xu
Journal:  Cell Mol Life Sci       Date:  2017-09-01       Impact factor: 9.261

8.  Changes in serum cytokine levels, hepatic and intestinal morphology in aflatoxin B1-induced injury: modulatory roles of melatonin and flavonoid-rich fractions from Chromolena odorata.

Authors:  Fadeyemi Joseph Akinrinmade; Akinleye Stephen Akinrinde; Adetayo Amid
Journal:  Mycotoxin Res       Date:  2016-01-22       Impact factor: 3.833

9.  Age-related differences in the response of the brain to dietary melatonin.

Authors:  Arezoo Campbell; Edward Sharman; Stephen C Bondy
Journal:  Age (Dordr)       Date:  2013-05-22

Review 10.  Novel therapeutic strategies for traumatic brain injury: acute antioxidant reinforcement.

Authors:  Rodrigo Fernández-Gajardo; José Manuel Matamala; Rodrigo Carrasco; Rodrigo Gutiérrez; Rómulo Melo; Ramón Rodrigo
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.